Nektar Therapeutics

NKTR

Market cap $2.31B

SAN FRANCISCO, June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on June 19, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 20,500 shares of its common stock and 3,900 restricted stock units (RSUs) to seven newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Nektar (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Nektar, pursuant to Nasdaq Listing Rule 5635(c)(4).

Robin sold 20,000 shares over two days for a transaction value of $1.22 million at a weighted average price of $60.75 per share. This sale represented 26.64% of his direct common stock holdings and reduced his direct position from 75,073 to 55,045 shares.

Big pharma's appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV | ABBV Price Prediction), targeting an atopic dermatitis and immunology developer, has reignited a question every healthcare portfolio manager is asking: who will be next?

SAN FRANCISCO, June 3, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on May 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 11,900 shares of its common stock to five newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Nektar (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Nektar, pursuant to Nasdaq Listing Rule 5635(c)(4).

SAN FRANCISCO, May 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York. 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 – webcast to be available at 1:20 p.m.

Nektar Therapeutics NASDAQ: NKTR outlined plans to advance its lead regulatory T-cell (Treg) therapy rezpegaldesleukin (REZPEG) into late-stage development, while also reporting first-quarter 2026 financial results and providing updates across its pipeline during its earnings call. Get Nektar Therapeutics alerts:Sign UpREZPEG positioned for phase III in atopic dermatitis President and CEO Howard Robin said the company is “exceptionally proud” of progress over the past year and highlighted phase IIb results in atopic dermatitis and alopecia areata that he said demonstrate clinically meaningful outcomes in two “distinct autoimmune and inflammatory disease settings.

NKTR misses Q1 earnings and revenue estimates. Investor focus stays on rezpeg as the company advances late-stage studies in autoimmune diseases.

Nektar Therapeutics (NKTR) Q1 2026 Earnings Call Transcript

SAN FRANCISCO, May 7, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2026. Cash and investments in marketable securities on March 31, 2026, were $731.6 million as compared to $245.8 million on December 31, 2025.

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 26-cv-01951, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Nektar securities between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.